Clin2
NCT04793633Possibly a fitEnrolling by invitation

Testing a noninvasive way to collect pancreatic cells early

Pancreatic Ductal Adenocarcinoma

Part of Cancer clinical trials.

This study tests LINFU™, a noninvasive method to collect pancreatic cells to help detect pancreatic cancer earlier. You may be invited if you’re at higher risk or you have concerning symptoms and planned pancreas/bile testing (like EUS or CT).

Summary written for real people, not researchers, by Clin2.

Phase
N/A
Enrollment
500 people
Ages
18 years to 90 years
Study type
Observational

Who can take part

  • Be between ages 18 and 89
  • You’re being checked because you’re at higher risk for pancreatic cancer or you have symptoms/imaging that look concerning
  • You must be able to sign consent approved by the study team’s review board
  • You are not pregnant, and you don’t have a pregnancy risk that makes you ineligible
  • You should be able to safely undergo the planned procedure(s) (like EUS/ERCP) without unsafe bleeding risk, serious anesthesia problems, or an unstable health condition
  • You can’t have an allergy to the microbubble contrast dye or secretin

View the official record on ClinicalTrials.gov

Quick eligibility check

Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.

Similar studies

Other trials that look related to this one.

NCT06276803Not yet recruiting
Pancreatic cancer screening study for healthy adults

This trial is studying a new screening method (LINFU®) to find pancreatic cancer early in people who have no symptoms or known risk factors, to see if it can help detect cancer in the general population.

NCT06330441Recruiting
Pancreatic cancer screening for high-risk groups

This study screens people at high risk for pancreatic cancer using imaging tests. It aims to catch cancer early in those with certain genetic conditions or strong family history.

Brno
NCT06574620Recruiting
Studying tumor DNA and proteins in pancreatic cancer

This study is looking at genetic material and proteins from pancreatic tumors to understand how the cancer responds to treatment. It aims to help doctors choose the best therapies for patients with certain types of pancreatic cancer that can be removed surgically or that have not spread to other organs.

Vancouver, British Columbia
NCT06157671Enrolling by invitation
Testing a new method to find early pancreatic cancer in high-risk people

This study is testing a new imaging method called LINFU® to see if it can find pancreatic cancer early in people who are at higher risk but have no symptoms. If you are at elevated risk for pancreatic cancer and are already getting imaging tests, this study may help improve early detection.

New York, New York
NCT06276738Not yet recruiting
Tracking a new imaging test for pancreatic cancer

This study tests a new imaging procedure called LINFU® that may help doctors better detect pancreatic cancer. You may join if you have symptoms or an abnormal scan that suggests pancreatic cancer, and you're scheduled for a biopsy.

NCT06666803Recruiting
Personalized profile of pancreatic tumors from biopsy samples

This study will take a close-up look at your pancreatic tumor by using a sample from a biopsy to create a personal profile. The goal is to understand your cancer better and maybe find the best treatment for you.

Strasbourg

Hear when a new Pancreatic Ductal Adenocarcinoma trial opens

We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.